4.7 Review

The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease

期刊

BIOMOLECULES
卷 12, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/biom12081150

关键词

PA200; PSME4; proteasome

资金

  1. BMBF (German Ministry of Research) [16GW0287]

向作者/读者索取更多资源

This article discusses the role and dysregulation of the proteasome regulator PA200 in human diseases, highlighting its potential as a therapeutic target in cancer.
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据